Cited by 1,281Clostridium difficile and Clostridium perfringens researchGut microbiota and healthAntibiotic Resistance in Bacteria

Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant

Open access
DeFilipp, Zachariah, Bloom, Patricia P., Torres Soto, Mariam, Mansour, Michael K., Sater, Mohamad R.A., Huntley, Miriam H., Turbett, Sarah, Chung, Raymond T. +2 more·2019·New England Journal of Medicine

Abstract

bacteremia occurred after they had undergone FMT in two independent clinical trials; both cases were linked to the same stool donor by means of genomic sequencing. One of the patients died. Enhanced donor screening to limit the transmission of microorganisms that could lead to adverse infectious events and continued vigilance to define the benefits and risks of FMT across different patient populations are warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1910437

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • FMT may carry the risk of unintended introduction of pathogens and antibiotic-resistant microbes into recipients.

    “FMT may also carry the risk of unintended introduction of pathogens and antibiotic-resistant microbes into the recipients.749,750”
  • In 2019, it was reported that in two independent clinical trials, two patients developed bacteremia with ESBL-producing Escherichia coli after receiving FMT from the same donor, and one patient died.

    “In 2019, it was reported that in two independent clinical trials, two patients developed bacteremia with extended-spectrum β-lactamase (ESBL)-producing Escherichia coli after receiving FMT from the same donor, and one patient died [136].”
  • Transmission of an extended-spectrum beta-lactamase-producing Escherichia coli strain from a stool donor to two immunocompromised recipients caused bacteremia, with a fatal outcome in one case.

    “This issue has become extremely timely after the transmission of an extended-spectrum b -lactamase-producing Escherichia coli strain from a stool donor to two immunocompromised recipients who developed bacteremia, with a fatal outcome in one case. 46”
  • Two cases of MDR bacteria transmission with life-threatening complications have been described in patients with cirrhosis and hematological malignancy after repeated FMT.

    “Indeed, two cases of MDR bacteria transmission with life-threatening complications have been described in patients with cirrhosis and hematological malignancy after repeated FMT. 46”
  • FMT is generally recognized as safe, with no or limited side effects, but unexpected toxicity has been reported, including ESBL-producing Escherichia coli bacteremia in two patients who received FMT.

    “Although FMT is generally recognized as safe, with no or limited side effects,33 unexpected toxicity has been reported, e.g., extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli bacteremia in two patients who received FMT.34”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Gupta A, Cifu AS, Khanna S. Diagno- sis and treatment of Clostridium difficile in- fection. JAMA 2018; 320: 1031-2.

Cited by

Sorted by citations

Authors
DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. A., Huntley, M. H., Turbett, S., Chung, R. T., Chen, Y.-B., & Hohmann, E. L.
Affiliations
  • Harvard University (US)
  • From the Blood and Marrow Transplant Program (Z.D., Y.-B.C.), the Liver Center, Division of Gastroenterology (P.P.B., R.T.C.), and the Division of Infectious Diseases (M.T.S., M.K.M., S.T., E.L.H.), Massachusetts General Hospital, Harvard Medical School (Z.D., P.P.B., M.T.S., M.K.M., S.T., R.T.C., Y.-B.C., E.L.H.), and Day Zero Diagnostics (M.R.A.S., M.H.H.) — all in Boston.
Venue
New England Journal of Medicine
Published
2019-11-21
Volume
381
Issue
21
Pages
2043-2050
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2982566732
Cited by
1,281
References
26
Citations by year
2026: 202 · 2025: 160 · 2024: 158 · 2023: 175 · 2022: 169 · 2021: 184 · 2020: 222 · 2019: 10
FWCI
112.06
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Massachusetts General Hospital
Topics
  • Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Medicine › Antibiotic Resistance in Bacteria
Keywords
drug-resistant Escherichia coli, bacteremia, fecal microbiota transplantation, donor screening, genome sequencing
MeSH terms
Fecal Microbiota Transplantation, Aged, beta-Lactamases, Escherichia coli, Feces, Hepatic Encephalopathy, Humans, Male, Myelodysplastic Syndromes, Bacteremia, Fatal Outcome, Drug Resistance, Bacterial, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review